Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zervimesine - Cognition Therapeutics

Next Previous
Search
Drug Profile

Zervimesine - Cognition Therapeutics

Alternative Names: CT-1812; Elayta

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cognition Therapeutics
  • Developer Alzheimers Clinical Trials Consortium; Cognition Therapeutics
  • Class Antidementias; Antiparkinsonians; Eye disorder therapies; Isoindoles; Neuroprotectants; Nootropics; Phenols; Small molecules; Sulfones
  • Mechanism of Action Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Dementia; Dry age-related macular degeneration
  • Preclinical Parkinson's disease
  • Discontinued Cognition disorders

Most Recent Events

  • 01 Apr 2025 Pharmacodynamics data from the phase II SHINE trial in Alzheimer’s disease released by Cognition Therapeutics
  • 28 Mar 2025 Cognition Therapeutics terminates phase-II clinical trials in Dry age-related macular degeneration in USA (PO) due to strategic business decision (NCT05893537)
  • 20 Mar 2025 Cognition Therapeutics plans to schedule an end-of-phase II meetings with the US FDA to review the results and to discuss the phase III trial protocol for Alzheimer's disease and Dementia in early second quarter of 2025

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top